相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting Programmed Cell Death-1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
Anastasia Constantinidou et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
A. B. Schrock et al.
ANNALS OF ONCOLOGY (2019)
Hepatobiliary Cancers, Version 2.2019 Featured Updates to the NCCN Guidelines
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer
Megan Greally et al.
CLINICAL CANCER RESEARCH (2019)
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
Omid Hamid et al.
CLINICAL CANCER RESEARCH (2019)
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Laura Fancello et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Tumor mutation burden: from comprehensive mutational screening to the clinic
Francesca Galuppini et al.
CANCER CELL INTERNATIONAL (2019)
Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
Conor E. Steuer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report
Yuki Owada-Ozaki et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer
Yanis Boumber
JOURNAL OF THORACIC DISEASE (2018)
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Jake R. Conway et al.
GENOME MEDICINE (2018)
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
Jordi Bruix et al.
JOURNAL OF HEPATOLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes?
Prashant Bhangui et al.
ANNALS OF SURGERY (2016)
Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion
Takashi Kokudo et al.
JOURNAL OF HEPATOLOGY (2016)
When to Perform Hepatic Resection for Intermediate-Stage Hepatocellular Carcinoma
Alessandro Cucchetti et al.
HEPATOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
分享论文
